Drug levels spike and crash rather than maintaining a consistent therapeutic level
Analogous to the gut-pancreas connection, which identified the incretin effect relating to insulin secretion, early studies proposed the existence of a so-called gut-kidney axis
In clinical trials, a gradual dose-escalation schedule was used specifically to allow the body to adapt and to minimise discomfort
New obesity drugs, beyond Ozempic/Wegovy, are working on the key drawbacks of GLP-1 namely tolerability
Social media influencers are touting a new option for popular weight loss drugs: GLP-1 patches, they say, are just as powerful as Ozempic for shedding pounds without the discomfort of needles or the hassle of getting a prescription
Ongoing supervision by a healthcare provider is essential to determine when it may be appropriate to stop semaglutide or consider switching to another weight loss medication